Skip to content
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Home
(current)
Diseases
Parkinson's Disease
Multiple Sclerosis and Related Disorders
Headache
Amyotrophic Lateral Sclerosis
Epilepsy
Sleep Disorders
Stroke
Neuromuscular Disorders
Movement Disorders
View all Diseases
Topics
Biology
Diagnostics
Trial Updates
Treatment
Prevention
Surgery
Imaging
Genetics
COVID-19
View all Topics
Conferences
EHC 2022
AES 2022
WSC 2022
ECTRIMS 2022
EHDN 2022
MDS 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Lawrence Steinman
3:57
The molecular basis of EBV triggering multiple sclerosis
Lawrence Steinman
• 11 Apr 2022
2:54
Important lines of research in progressive multiple sclerosis
Lawrence Steinman
• 11 Apr 2022
1:52
Relapse rate from the ULTIMATE studies of ublituximab for relapsing MS
Lawrence Steinman
• 11 Apr 2022
3:26
Phase III ULTIMATE I & II update: ublituximab versus teriflunomide in relapsing MS
Lawrence Steinman
• 15 Oct 2021
1:41
Ublituximab: pending approval for relapsing MS
Lawrence Steinman
• 15 Oct 2021
1:14
How does ublituximab compare to other anti-CD20 mAbs?
Lawrence Steinman
• 15 Oct 2021
3:27
ULTIMATE I & II results: ublituximab versus teriflunomide in relapsing MS
Lawrence Steinman
• 11 Jun 2021
3:08
Novel agents are needed for the treatment of multiple sclerosis
Lawrence Steinman
• 11 Jun 2021
